Analytical Data
-
Gene name
GDF2
- Application
-
Alternative Names
Bone morphogenetic protein 9 Short name: BMP-9
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UK05
-
Expression Region
300-429aa
-
Molecular Weight
16.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The GDF2 (Growth Differentiation Factor 2), a member of the transforming growth factor-beta (TGF-β) superfamily, plays a crucial role in various biological processes, including embryonic development, tissue repair, and hematopoiesis. Notably, GDF2 is involved in the regulation of vascular biology and is essential for the maintenance of vascular homeostasis. Research has shown that GDF2 mediates signaling pathways that influence angiogenesis and the differentiation of endothelial cells, making it a key factor in cardiovascular health. Abnormalities in GDF2 expression have been linked to several pathological conditions, such as pulmonary arterial hypertension and other cardiovascular diseases. Consequently, GDF2 recombinant protein has become a focus of study, as it can serve as a valuable tool for investigating its biological functions and potential therapeutic applications. Studies involving GDF2 recombinant protein aim to elucidate its role in vascular development and disease, assess its potential as a biomarker, and explore its therapeutic implications in restoring normal vascular function. By employing recombinant technology, researchers can produce GDF2 in sufficient quantities for in vitro and in vivo studies, allowing for a better understanding of its signaling mechanisms and effects on vascular biology. As research progresses, GDF2 may emerge as a promising target for innovative therapeutic strategies aimed at addressing cardiovascular disorders and enhancing tissue regeneration.
